1774353-12-6
Chemical Structure
6bK TFA
- CAS No.: 1774353-12-6
- Formula:C43H56F3N7O9
- Molecular Weight:871.94
IUPAC Name: (3R,6S,9S,16S,E)-9-(4-aminobutyl)-3-(4-benzoylbenzyl)-6-(cyclohexylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentaazacycloicos-12-ene-16-carboxamide 2,2,2-trifluoroacetate
InChIKey: YYZNAMZJUJTYPS-GNVBVUGKSA-N
SMILES: O=C(N[C@@H](C(NCCCC[C@H]1C(N)=O)=O)CC(C=C2)=CC=C2C(C3=CC=CC=C3)=O)[C@@H](NC([C@@H](NC(/C=C/C(N1)=O)=O)CCCCN)=O)CC4CCCCC4.OC(C(F)(F)F)=O
Biological Activity: 6bK TFA is a selective insulin-degrading enzyme (IDE) inhibitor with an IC50 of 50 nM. 6bK TFA binds to the distal pocket of IDE, thereby blocking substrate binding, peptide unfolding and cleavage processes, and reducing the degradation of insulin, glucagon and amylin. 6bK TFA improves oral glucose tolerance but impairs intraperitoneal glucose tolerance. 6bK TFA can be used in research related to type 2 diabetes[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
6bK TFA | 99.68% | 6bK TFA is a selective insulin-degrading enzyme (IDE) inhibitor with an IC50 of 50 nM. 6bK TFA binds to the distal pocket of IDE, thereby blocking substrate binding, peptide unfolding and cleavage processes, and reducing the degradation of insulin, glucagon and amylin. 6bK TFA improves oral glucose tolerance but impairs intraperitoneal glucose tolerance. 6bK TFA can be used in research related to type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
6bK TFA (Standard) | ≥98% | 6bK TFA (Standard) is the analytical standard of 6bK (TFA) (HY-110197). This product is intended for research and analytical applications. 6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice. 6bK TFA can be used for type 2 diabetes research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Costes S, et al. Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?. Cell Metab. 2014;20(2):201-203. [Content Brief]
- [2]. Maianti JP, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511(7507):94-98. [Content Brief]
